H.C. Wainwright assumed coverage of Cidara Therapeutics (CDTX) with a Buy rating and $41 price target Cidara is developing CD388, the company’s lead influenza drug-Fc conjugate candidate in development for the prevention of all strains of influenza A and B, the analyst tells investors in a research note. The firm says that with a high unmet need, current influenza vaccines and antivirals don’t adequately protect against high risk patient populations.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Optimistic Buy Rating for Cidara Therapeutics Ahead of Phase 2b Flu Trial Results
- Strong Buy Rating for Cidara Therapeutics: CD388’s Revolutionary Potential in Flu Treatment and Beyond
- Cidara Therapeutics price target raised to $35 from $31 at RBC Capital
- Cidara Therapeutics price target raised to $50 from $35 at Guggenheim
- Promising Developments and Upcoming Data Release Drive Buy Rating for Cidara Therapeutics